| Autor: |
Narek Shaverdian, MD, Michael Offin, MD, Annemarie F. Shepherd, MD, Matthew D. Hellmann, MD, Daniel R. Gomez, MD, Jamie E. Chaft, MD, Andreas Rimner, MD |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
JTO Clinical and Research Reports, Vol 2, Iss 7, Pp 100197- (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2666-3643 |
| DOI: |
10.1016/j.jtocrr.2021.100197 |
| Popis: |
Introduction: Durvalumab after concurrent chemoradiation (cCRT) has been found to improve outcomes of patients with unresected stage III NSCLC. However, the survival impact of discontinuing durvalumab early owing to adverse events (AEs) remains unknown. Methods: Patients with stage III NSLCC treated with cCRT and greater than or equal to one dose of durvalumab across a multisite cancer center were evaluated. The median durvalumab treatment duration among patients who discontinued owing to AEs (2.1 mo) defined two patient cohorts: early discontinuation ( |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
